pharmtech
Economic performance could soon replace compliance as the leading quality goal for pharmaceutical companies.
According to the 2019 Pharma Quality Outlook Survey, 66% of industry executives named compliance as a top goal, down 10% from last year. Meanwhile, more than one-third (39%) say that economic performance is now their top objective, a 4% increase.Join Sparta System's Steve McCarthy, VP of Digital Innovation, as he discusses key findings from this year's survey, which included responses from 161 professionals.
Watch Now
quotientsciences
Many pharma companies are seeking new ways of making drug development more efficient and cost-effective through innovation, new technologies and process evolution. This has led to an increase in the outsourcing of development activities to contract research partners who focus solely on disciplines such as discovery chemistry, clinical testing, and formulation development and manufacturing.
Watch Now
Ambry Genetics
This webinar will review clinical and genetic risk factors for contralateral breast cancer in patients who have been newly diagnosed with breast cancer. A specific focus on the role of family history and genetic mutations on contralateral breast cancer risk will be outlined. The role of risk models and how to apply these and other prediction tools in the clinical setting will be reviewed.
Watch Now
There has been growing interest in Pichia for use in the production of biopharmaceuticals including: SARS CoV2 spike protein and RBD, antibodies and other proteins for medicinal purposes.
Watch Now